Atlas Trials

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Clinical trial NCT02984995 · COMPLETED

Trial details

NCT number
NCT02984995
Sponsor
Daiichi Sankyo Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Leukemia, Myeloid, Acute
Start date
2016-12-08
Primary completion
2018-03-28
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.